ABC in the news

摘要

Patients who are on a triple nucleoside reverse transcriptase inhibitor (NRTI) regimen with abacavir (ABC) as their third drug are significantly more likely to experience a rebound in their viral load, even if they achieve durable suppression of HIV, than patients who take the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV) as their third antiretroviral drug Italian investigators writing in the July 1, 2006, edition of the Journal of Infectious Diseases recommend that patients who take ABC combined with the NRTIs lamivudine (3TC) and zidovudine (ZDV), stavudine (d4T) and 3TC, or d4T and didanosine (ddl) should switch to a more potent antiretroviral regimen, regardless of whether they have durable viral suppression.